We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ADMA Appoints James Mond as Chief Medical and Scientific Officer

News   Jul 27, 2012

 
ADMA Appoints James Mond as Chief Medical and Scientific Officer
 
 
 

RELATED ARTICLES

Some Cancer Drugs Don’t Work by Hitting Their Targets

News

Some cancer drug candidates in clinical trials kill cancerous cells through off-target effects instead of by interacting with their intended molecular targets, according to new study findings.

READ MORE

Drug That Combats Memory Loss in Alzheimer's Enters Phase II Trials

News

A new drug may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease. The drug called BPN14770 is now in Phase 2 clinical trials in patients with Alzheimer's and Fragile X syndrome.

READ MORE

Compound Created to Help Reconstruct Myelin in Multiple Sclerosis

News

Researchers have created a compound, that when tested in mice, was able to promote the reconstruction of the myelin sheath surrounding neuronal axons. These findings could pave the way to a new treatment for combating demyelinating conditions such as multiple sclerosis.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE